邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

体现实践成果, 引领未来方向:国际妇产科联盟2018年宫颈癌分期解读

彭澎,  向阳

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(1): 12-15
彭澎, 向阳. 体现实践成果, 引领未来方向:国际妇产科联盟2018年宫颈癌分期解读[J]. 协和医学杂志, 2020, 11(1): 12-15. doi: 10.3969/j.issn.1674-9081.20190164
引用本文: 彭澎, 向阳. 体现实践成果, 引领未来方向:国际妇产科联盟2018年宫颈癌分期解读[J]. 协和医学杂志, 2020, 11(1): 12-15. doi: 10.3969/j.issn.1674-9081.20190164
shu
Peng PENG, Yang XIANG. Reflecting the Achievements of Practice and Leading the Future Direction: Interpretation on Cervical Cancer Staging of the International Federation of Obstetrics and Gynecology in 2018[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 12-15. doi: 10.3969/j.issn.1674-9081.20190164
Citation: Peng PENG, Yang XIANG. Reflecting the Achievements of Practice and Leading the Future Direction: Interpretation on Cervical Cancer Staging of the International Federation of Obstetrics and Gynecology in 2018[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 12-15. doi: 10.3969/j.issn.1674-9081.20190164
shu

体现实践成果, 引领未来方向:国际妇产科联盟2018年宫颈癌分期解读

doi: 10.3969/j.issn.1674-9081.20190164

  • 中国医学科学院 北京协和医学院 北京协和医院妇科肿瘤中心, 北京 100730

基金项目: 

中国医学科学院医学与健康科技创新工程 2017-I2M-1-002

详细信息
    通讯作者:

    向阳 电话:010-69156204, E-mail:xiangy@pumch.cn

  • 中图分类号: R713

Reflecting the Achievements of Practice and Leading the Future Direction: Interpretation on Cervical Cancer Staging of the International Federation of Obstetrics and Gynecology in 2018

  • Department of Gynecological Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
    Corresponding author: XIANG Yang Tel: 86-10-69156204, E-mail:xiangy@pumch.cn

    摘要
  • 摘要: 一直以来, 国际妇产科联盟(International Federation of Gynecology and Obstetrics, FIGO)的宫颈癌分期都是临床分期。但随着诊断技术的发展、手术方式的进步以及对宫颈癌预后的了解加深, 过去的FIGO分期已不能很好地推测宫颈癌预后及指导临床治疗选择。因此, FIGO在2009年宫颈癌分期的基础上, 引入了近10年来宫颈癌诊治的新进展, 形成了2018年宫颈癌分期。新的分期主要体现在肿瘤大小的分层更加细化, 且纳入了淋巴结转移情况。本文对FIGO的2018年宫颈癌分期变化及其临床意义进行解读。
    Abstract: For years, the cervical cancer staging of the International Federation of Gynecology and Obstetrics (FIGO) are of clinical staging. However, with the development of diagnostic techniques, advances in surgical procedures, and a deeper understanding of the prognosis of cervical cancer, the old FIGO staging has not been able to well predict the prognosis of cervical cancer and to help the choice of treatment. Therefore, on the basis of the cervical cancer staging in 2009, FIGO introduced new progress in the diagnosis and treatment of cervical cancer in the past 10 years and formed the new staging of cervical cancer in 2018. The new staging system mainly reflects a more detailed stratification of the tumor size and the inclusion of lymph node metastasis. This article explains the changes in the cervical cancer staging of FIGO 2018 and its clinical significance.
    利益冲突  无
    • HTML全文
    • 参考文献(17)
  • [1] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium[J]. Int J Gynaecol Obstet, 2009, 105:103-104. doi:  10.1016/j.ijgo.2009.02.012
    [2] Bhatla N, Denny L.FIGO Cancer Report 2018[J]. Int J Gynaecol Obstet, 2018, 143:2-3. https://www.ncbi.nlm.nih.gov/pubmed/30306587
    [3] Matsuo K, Machida H, Mandelbaum RS, et al. Trachelectomy for stage IB1 cervical cancer with tumor size >2 cm:trends and characteristics in the United States[J]. J Gynecol Oncol, 2018, 29:e85.
    [4] Machida H, Mandelbaum RS, Mikami M, et al. Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer:trachelectomy vs hysterectomy[J]. Am J Obstet Gynecol, 2018, 219:461.e1-461.e18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648708/
    [5] Li J, Wu X, Li X, et al. Abdominal radical trachelectomy:Is it safe for IB1 cervical cancer with tumors >/=2 cm?[J]. Gynecol Oncol, 2013.131:87-92. doi:  10.1016/j.ygyno.2013.07.079
    [6] Plante M.Evolution in fertility-preserving options for early-stage cervical cancer:radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapy[J]. Int J Gynecol Cancer, 2013, 23:982-989. doi:  10.1097/IGC.0b013e318295906b
    [7] Marchiole P, Benchaib M, Buenerd A, et al. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation):a comparative study with laparoscopic-assisted vaginal radical hysterectomy(LARVH)[J]. Gynecol Oncol, 2007, 106:132-141. doi:  10.1016/j.ygyno.2007.03.009
    [8] Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer?[J]. Gynecol Oncol, 2004, 92:525-529. doi:  10.1016/j.ygyno.2003.11.020
    [9] Selman TJ, Mann C, Zamora J, et al. Diagnostic accuracy of tests for lymph node status in primary cervical cancer:a systematic review and meta-analysis[J]. CMAJ, 2008, 178:855-862. doi:  10.1503/cmaj.071124
    [10] Singh N, Arif S.Histopathologic parameters of prognosis in cervical cancer-a review[J]. Int J Gynecol Cancer, 2004, 14:741-750.
    [11] Ramirez PT, Jhingran A, Macapinlac HA, et al.Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer:a prospective correlation of surgical findings with positron emission tomography/computed tomography findings[J]. Cancer, 2011, 117:1928-1934. doi:  10.1002/cncr.25739
    [12] Pol FJ, Zusterzeel PL, van Ham MA, et al.Satellite lymphovascular space invasion:An independent risk factor in early stage cervical cancer[J]. Gynecol Oncol, 2015, 138:579-584. doi:  10.1016/j.ygyno.2015.06.035
    [13] Hutchcraft ML, Smith B, McLaughlin EM, et al.Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer[J]. Gynecol Oncol, 2019, 153:255-258. doi:  10.1016/j.ygyno.2019.01.026
    [14] Sedlis A, Bundy BN, Rotman MZ, et al.A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy:A Gynecologic Oncology Group Study[J]. Gynecol Oncol, 1999, 73:177-183. doi:  10.1006/gyno.1999.5387
    [15] Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system[J]. Gynecol Oncol, 2019, 152:87-93. doi:  10.1016/j.ygyno.2018.10.026
    [16] Wright JD, Matsuo K, Huang Y, et al.Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines[J]. Obstet Gynecol, 2019, 134:49-57. doi:  10.1097/AOG.0000000000003311
    [17] Ayhan A, Aslan K, Oz M, et al. Para-aortic lymph node involvement revisited in the light of the revised 2018 FIGO staging system for cervical cancer[J]. Arch Gynecol Obstet, 2019, 300:675-682. doi:  10.1007/s00404-019-05232-7
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  385
  • HTML全文浏览量:  29
  • PDF下载量:  352
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-08-07
  • 刊出日期:  2020-01-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！